1. Scrip
  2. >>Business
  3. >>Strategy

Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma

 
• By Mandy Jackson

Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.

Eye

Allergan PLC frequently talks about wanting to “own the face” in terms of its aesthetic medicine business, but the company also is increasing its focus on the eye with products for various ophthalmic conditions – an area in which Allergan management has deep experience.

The second highest-selling product in Allergan’s portfolio – behind the wrinkle-reducing and migraine-busting Botox (onabotulinumtoxinA) – is the blockbuster Restasis (cyclosporine) for dry eye disease, which is facing new competition. But the company also inherited as part of its $66bn namesake acquisition in 2015 a portfolio of glaucoma drugs, a drug-device combination product, and the beginnings of a diverse ophthalmology research and development pipeline, including therapeutics, devices and surgical procedures

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

More from Business

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.